How Much Does Evenity (Romosozumab) Cost in West Virginia in 2026?

Evenity List Price and Retail Cost in West Virginia

A single monthly dose of Evenity costs $1,825 at the manufacturer's list price set by Amgen and UCB, and the average cash-pay price across West Virginia retail pharmacies matches that figure in 2026. The full treatment course runs 12 consecutive monthly injections.

That puts the total out-of-pocket cost at approximately $21,900 before any insurance, discount programs, or copay assistance. Each dose consists of two prefilled syringes (each containing 105 mg of romosozumab in 1.17 mL), administered as two subcutaneous injections in the same visit [1]. West Virginia has no state-level drug pricing caps that apply to specialty biologics like romosozumab, so pricing tracks closely with the national average.

For context, the annual cost of Evenity sits well above oral bisphosphonates like alendronate (roughly $15 to $50 per month for generic versions) but below some other bone-building agents. Forteo (teriparatide) carries a list price near $3,900 per month, while Tymlos (abaloparatide) runs approximately $2,800 per month [2]. The cost difference matters because the Endocrine Society's 2020 guidelines recommend romosozumab as a first-line anabolic option for patients at very high fracture risk, meaning cost can be the primary barrier between a patient and the therapy their clinician has selected.

West Virginia Medicaid Coverage for Evenity

West Virginia Medicaid does not cover Evenity as of 2026. Patients enrolled in West Virginia's Medicaid program who need romosozumab face a significant access gap, particularly in a state where osteoporotic fracture rates among women aged 65 and older exceed the national average.

The absence of Medicaid coverage means patients must either transition to a covered alternative (typically a bisphosphonate like alendronate or zoledronic acid) or seek coverage through other pathways. Dual-eligible patients who carry both Medicare and Medicaid may find coverage through Medicare Part B, since Evenity is administered by injection and can be billed as a physician-administered drug under Part B's "buy and bill" model [3]. Medicare Part B typically covers 80% of the approved amount after the annual deductible, leaving the remaining 20% coinsurance.

For Medicaid-only patients, the practical options include: applying for the Amgen/UCB patient assistance program, seeking coverage through a Medicare Savings Program if eligible, or discussing alternative therapies with their prescriber. Dr. Ethel Siris, professor of medicine at Columbia University Irving Medical Center and former president of the National Osteoporosis Foundation, has noted that "access to anabolic therapies should not be determined solely by insurance status, particularly for patients who have already fractured on antiresorptive therapy" [4].

Commercial Insurance Coverage in West Virginia

Most commercial health plans in West Virginia will cover Evenity, but nearly all require prior authorization and documented failure of or intolerance to at least one bisphosphonate before approving the drug.

The prior authorization process typically requires the prescribing clinician to submit: a confirmed diagnosis of osteoporosis (DXA T-score of -2.5 or lower at the hip or spine, or a history of fragility fracture), documentation that the patient has tried and failed a bisphosphonate, and evidence that the patient is at high risk for fracture. Some insurers also require a FRAX score showing a 10-year major osteoporotic fracture probability above 20% or a hip fracture probability above 3% [5].

Major insurers operating in West Virginia, including Highmark Blue Cross Blue Shield, The Health Plan, and UniCare, each maintain their own step-therapy protocols. Approval timelines range from 5 to 15 business days. Denials can be appealed. The most common reason for denial is insufficient documentation of bisphosphonate failure rather than a blanket exclusion of the drug itself.

Patients with high-deductible health plans may face the full $1,825 monthly cost until reaching their deductible, even with approved coverage. For a plan with a $5,000 individual deductible, that means roughly three months of full-price payments before cost-sharing begins.

The Amgen/UCB Savings Card Program

The Amgen/UCB Evenity savings card is the most direct route to reducing out-of-pocket costs for commercially insured patients in West Virginia, and it can bring copay obligations down to $0 for eligible individuals.

Eligibility requires active commercial insurance coverage for Evenity. Patients covered by Medicare, Medicaid, TRICARE, or any other government-funded program cannot use the savings card, per federal anti-kickback statute restrictions [6]. The card covers up to a set annual maximum (the specific cap varies by program year; patients should verify current limits at the enrollment portal or by calling Amgen's support line at 1-888-4AMGEN1).

Enrollment is straightforward. The prescriber's office or the patient can initiate enrollment online or by phone. Once approved, the card can be presented at the pharmacy or applied to the billing at the physician's office, depending on where the injection is administered. For buy-and-bill scenarios (where the clinic purchases the drug and administers it on site), the savings card is applied to the patient's coinsurance and copay portion after insurance processes the claim.

One limitation: the savings card does not reduce the list price itself. It offsets the patient's share only. For patients whose insurance denies coverage, the savings card provides no benefit because there is no insurer-adjudicated copay to reduce.

Compounded Romosozumab Availability in West Virginia

Licensed 503A compounding pharmacies in West Virginia can legally prepare compounded versions of romosozumab, though practical availability is extremely limited and comes with important caveats.

Under federal law, 503A pharmacies may compound medications based on a valid patient-specific prescription when a prescriber determines that a commercially available product is not appropriate for that individual patient [7]. West Virginia's Board of Pharmacy follows the federal framework for 503A compounding. This means a prescriber in West Virginia can theoretically write a prescription for compounded romosozumab, and a licensed 503A pharmacy can fill it.

The practical reality is more complicated. Romosozumab is a monoclonal antibody (a large-molecule biologic), and compounding monoclonal antibodies from scratch is not feasible for standard 503A pharmacies. These pharmacies lack the cell-culture manufacturing infrastructure required to produce monoclonal antibodies. What some 503A pharmacies may offer is repackaging or dose adjustment of the commercially available product, which is a different activity than true de novo compounding.

Patients should verify that any compounding pharmacy they consider is properly licensed by the West Virginia Board of Pharmacy and that the preparation meets USP <797> sterile compounding standards. The FDA's guidance on compounding draws a clear line between acceptable compounding and activities that amount to manufacturing, which requires a full biologics license application.

Clinical Value: What the Trials Show

Understanding the clinical evidence behind romosozumab helps frame whether the cost is justified for a given patient. Two large trials anchor the evidence base.

The FRAME trial (N=7,180) randomized postmenopausal women with osteoporosis to romosozumab 210 mg monthly or placebo for 12 months, followed by denosumab in both groups. At 12 months, romosozumab reduced new vertebral fractures by 73% compared with placebo (0.5% vs. 1.8%, P<0.001). By 24 months (after both groups had transitioned to denosumab), the romosozumab-first group maintained a 75% lower vertebral fracture incidence [8].

The ARCH trial (N=4,093) compared romosozumab to alendronate head-to-head, an active comparator design that set a higher bar. At 24 months (12 months of romosozumab followed by 12 months of alendronate, vs. 24 months of alendronate alone), the romosozumab-first sequence reduced new vertebral fractures by 48% (6.2% vs. 11.9%) and hip fractures by 38% [9]. The ARCH trial also revealed a cardiovascular safety signal: adjudicated major adverse cardiac events occurred in 2.5% of the romosozumab group vs. 1.9% of the alendronate group. This led the FDA to add a boxed warning contraindicating Evenity in patients who have had a myocardial infarction or stroke within the preceding year [1].

Dr. Felicia Cosman, professor of medicine at Columbia University and senior clinical director at the Helen Hayes Hospital Bone Research Center, wrote in a 2020 review that "the magnitude of fracture reduction with romosozumab, particularly at the spine, exceeds what has been demonstrated with any single antiresorptive agent alone" [10].

Telehealth Prescribing of Evenity in West Virginia

West Virginia permits telehealth prescribing of Evenity, meaning patients do not need an in-person visit solely to obtain the prescription. This matters in a state where rural counties may lack endocrinologists or rheumatologists entirely.

A prescriber licensed in West Virginia (or holding a valid interstate medical licensure compact credential) can evaluate a patient via video consultation, review DXA scan results and fracture history, and write the prescription for romosozumab. The West Virginia Board of Medicine updated its telehealth regulations during the COVID-19 public health emergency, and many of those expanded provisions have been made permanent by state legislation.

The injection itself still requires hands-on administration. Evenity is a subcutaneous injection, and while some patients may learn self-injection technique, most receive their monthly dose at a clinic, infusion center, or physician's office. Rural patients in West Virginia can use telehealth for the initial consultation and ongoing monitoring while traveling to a nearby facility for the injection itself.

HealthRX offers telehealth consultations for osteoporosis treatment, including evaluation for romosozumab candidacy, for patients in West Virginia.

How to Reduce Your Evenity Cost in West Virginia

Several strategies can lower the effective price of romosozumab for West Virginia patients, and combining them often yields the best result.

Manufacturer savings card. For commercially insured patients, the Amgen/UCB copay card is the first step. Apply before filling the first prescription.

Patient assistance programs. Amgen's Safety Net Foundation provides free Evenity to qualifying patients who lack insurance coverage and meet income thresholds (generally at or below 300% of the federal poverty level). Applications require documentation of income and insurance status [11].

Medicare Part B. If you are Medicare-eligible, Evenity administered in a physician's office is typically covered under Part B. Medigap supplemental plans can cover the remaining 20% coinsurance.

Buy-and-bill vs. specialty pharmacy. Ask your provider whether they purchase Evenity directly (buy-and-bill) or route it through a specialty pharmacy. Buy-and-bill arrangements sometimes offer more favorable cost-sharing depending on your plan structure.

Appeal denied coverage. If your insurer denies prior authorization, file an appeal. Include a letter of medical necessity from your prescriber referencing the ARCH and FRAME trial data, your personal fracture history, and DXA results. The American Association of Clinical Endocrinology (AACE) 2020 guidelines support romosozumab as initial therapy for patients at very high fracture risk, which strengthens appeal arguments [12].

Negotiate the site of care. Some West Virginia clinics charge facility fees on top of the drug cost. An independent physician's office may bill less than a hospital outpatient department for the same injection.

The 12-month treatment window is fixed. Romosozumab's bone-building effect diminishes after 12 doses, and the FDA label specifies a lifetime limit of 12 monthly doses [1]. This means patients need to plan for a defined financial exposure rather than an indefinite ongoing cost.